Cetuximab (Cmab) plus irinotecan (I) versus panitumumab (Pmab) in patients with refractory metastatic colorectal cancer (mCRC) in Ontario

被引：0
|
作者：
Jerzak, K. J. [1 ]
Earle, C. [1 ]
Ko, Y-J. [1 ]
Berry, S. [1 ]
Chan, K. K. [1 ]
机构：
[1] Sunnybrook HSC, Sunnybrook Odette Canc Ctr, Med, Toronto, ON, Canada
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw370.43
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
495P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Cetuximab plus irinotecan versus panitumumab in patients with refractory metastatic colorectal cancer in Ontario, Canada
    Jerzak, Katarzyna J.
    Berry, Scott
    Ko, Yoo-Joung
    Earle, Craig
    Chan, Kelvin K. W.
    INTERNATIONAL JOURNAL OF CANCER, 2017, 140 (09) : 2162 - 2167
  • [2] Panitumumab (Pmab) versus cetuximab (Cmab)/irinotecan (Iri) therapy among patients with KRAS wild-type (wt) metastatic colorectal cancer (MCRC).
    Kennecke, Hagen F.
    Chen, Leo
    Blanke, C. D.
    Cheung, Winson Y.
    Schaff, Kimberly
    Speers, Caroline
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [3] Irinotecan plus cetuximab (Cmab) versus irinotecan plus panitumumab (Pmab) in patients (pts) with wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) as third-line in daily practice
    Sugimoto, N.
    Hasegawa, A.
    Fujisawa, F.
    Yoshinami, T.
    Yagi, T.
    Imamura, F.
    ANNALS OF ONCOLOGY, 2016, 27
  • [4] Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer
    Braghiroli, Maria Ignez Freitas Melro
    Filho, Daniel Santos Rocha Sobral
    Fagundes, Juliana Goes Martins
    Mendoza, Elizabeth Zambrano
    Neffa, Maria Fernanda Batistuzzo Vicentini
    Campos, Karla Souza
    da Fonseca, Leonardo Gomes
    Bonadio, Renata Colombo
    Talans, Aley
    Braghiroli, Oddone Freitas Melro
    Mathias-Machado, Maria Cecilia
    Sabbaga, Jorge
    Venchiarutti, Camila Motta
    Hoff, Paulo Marcelo Gehm
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2024, 42
  • [5] A phase 2 study of mechanisms of acquired resistance to panitumumab (pmab) plus irinotecan (iri) for metastatic colorectal cancer (mCRC)
    Siena, S.
    Sartore-Bianchi, A.
    Karthaus, M.
    Smith, D.
    Garcia-Carbonero, R.
    Van Cutsem, E.
    Guan, X.
    Boedigheimer, M.
    Sidhu, R.
    Jung, A. S.
    Oliner, K. S.
    Tabernero, J.
    Bardelli, A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S394 - S395
  • [6] Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
    Cunningham, D
    Humblet, Y
    Siena, S
    Khayat, D
    Bleiberg, H
    Santoro, A
    Bets, D
    Mueser, M
    Harstrick, A
    Verslype, C
    Chau, I
    Van Cutsem, E
    NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04): : 337 - 345
  • [7] Motesanib with or without panitumumab (pmab) plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer (mCRC).
    Tebbutt, N. C.
    Kotasek, D.
    Burris, H. A., III
    Schwartzberg, L. S.
    Hurwitz, H.
    Stephenson, J.
    Adewoye, H.
    Sun, Y.
    Ye, Y.
    Goldstein, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [8] EFFICACY AND SAFETY OF CETUXIMAB PLUS IRINOTECAN IN IRINOTECAN-REFRACTORY ELDERLY PATIENTS (>65 YEARS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Jehn, C.
    Stenzel, K.
    Boening, L.
    Kroening, H.
    Possinger, K.
    Lueftner, D.
    ANNALS OF ONCOLOGY, 2010, 21 : 195 - 195
  • [9] Efficacy and safety of Cetuximab plus irinotecan in irinotecan-refractory elderly patients (>65 years) with metastatic colorectal cancer (mCRC)
    Jehn, C.
    Stenzel, K.
    Boening, L.
    Kroening, H.
    Possinger, K.
    Lueftner, D.
    ONKOLOGIE, 2010, 33 : 174 - 174
  • [10] Cetuximab plus irinotecan in refractory colorectal cancer patients
    Delgao, Marian Gil
    Spano, Jean-Philippe
    Khayat, David
    EXPERT REVIEW OF ANTICANCER THERAPY, 2007, 7 (04) : 407 - 413
12345